Johnson & Johnson has completed the acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to hormonally-driven cancers.
The Janssen Research & Development will manage compound development from Aragon's androgen receptor antagonist program, including ARN-509, its lead androgen receptor signaling inhibitor.
One of the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development is based in New-Jersey ith affiliated facilities in Europe, the US and Asia.
Janssen Research & Development oncology global therapeutic area head Peter Lebowitz said the acquisition strengthens prostate cancer pipeline with a second-generation, potentially best-in-class compound.
"It builds on our existing leadership position with ZYTIGA (abiraterone acetate), and, if ultimately approved, we are hopeful will allow us to meet the needs of an even broader range of prostate cancer patients," Lebowitz added.
